Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

McGill University

$40,000.00

The generation and testing of a cell-permeable constitutively active recombinant parkin protein for its neuroprotective properties

EF 2014-15

Résumé
Parkinson's disease (PD) is the second most common neurodegenerative disease in Canada, with ~50% of cases with an early onset linked to mutations in the PARK2 gene, which encodes the parkin protein. Parkin functions as an E3 ubiquitin (Ub) ligase that plays a neuroprotective role in a range of cellular and animal models of PD. Intriguingly, a recent study from my lab has provided the first evidence that parkin exists in an autoinhibited state. Thus, basal E3 activity of parkin is low, requiring activation. Remarkably, changing the W403 in parkin to an alanine abolished this inhibition, causing hyperactivation of parkin. Considering the neuroprotective properties of parkin, developing an active parkin protein presents a novel and exciting therapeutic avenue to explore in protecting neurons against stress in PD patients. Here we propose to partner with iProgen to take advantage of their proprietary iProgen Protein Transduction Domain (iPTD) to generate novel cell-permeable parkin proteins, that we would otherwise be unable to generate. Using this iPTD tag, iProgen will generate a W403A constitutively active parkin protein whose protective properties we will compare against a basally inactive wild-type parkin in cellular models of PD. In the first part of the project, iProgen will engineer, express and purify recombinant parkin proteins. In the second part of the project, we will test the in vitro ubiquitin ligase activity of the parkin proteins, and investigate their biological activity in cellular models of PD. If the present study demonstrates that the derepressed parkin protein can enhance cellular protection relative to the wild-type protein, these results provide impetus for further studies exploring the protective properties of this constitutively active parkin. For iProgen these results enable them to proceed towards the next stage of producing greater quanitites of the parkin protein for use in future trials.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
462000-2013
Name nom
Fon, Edward
Department département
Neurology and Neurosurgery
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2013
Award amount
40000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
The generation and testing of a cell-permeable constitutively active recombinant parkin protein for its neuroprotective properties
Keyword
NSERC
Application summary
Parkinson's disease (PD) is the second most common neurodegenerative disease in Canada, with ~50% of cases with an early onset linked to mutations in the PARK2 gene, which encodes the parkin protein. Parkin functions as an E3 ubiquitin (Ub) ligase that plays a neuroprotective role in a range of cellular and animal models of PD. Intriguingly, a recent study from my lab has provided the first evidence that parkin exists in an autoinhibited state. Thus, basal E3 activity of parkin is low, requiring activation. Remarkably, changing the W403 in parkin to an alanine abolished this inhibition, causing hyperactivation of parkin. Considering the neuroprotective properties of parkin, developing an active parkin protein presents a novel and exciting therapeutic avenue to explore in protecting neurons against stress in PD patients. Here we propose to partner with iProgen to take advantage of their proprietary iProgen Protein Transduction Domain (iPTD) to generate novel cell-permeable parkin proteins, that we would otherwise be unable to generate. Using this iPTD tag, iProgen will generate a W403A constitutively active parkin protein whose protective properties we will compare against a basally inactive wild-type parkin in cellular models of PD. In the first part of the project, iProgen will engineer, express and purify recombinant parkin proteins. In the second part of the project, we will test the in vitro ubiquitin ligase activity of the parkin proteins, and investigate their biological activity in cellular models of PD. If the present study demonstrates that the derepressed parkin protein can enhance cellular protection relative to the wild-type protein, these results provide impetus for further studies exploring the protective properties of this constitutively active parkin. For iProgen these results enable them to proceed towards the next stage of producing greater quanitites of the parkin protein for use in future trials.